Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
Melanoma Institute Australia
Dana-Farber Cancer Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
University of Washington
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Incyte Corporation
University of Pittsburgh
Weill Medical College of Cornell University
University Hospital, Essen
Melanoma and Skin Cancer Trials Limited
Memorial Sloan Kettering Cancer Center
ImmunityBio, Inc.
ImaginAb, Inc.
4SC AG
ImmunityBio, Inc.
EMD Serono
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
National Cancer Institute (NCI)
OncoSec Medical Incorporated
Dana-Farber Cancer Institute
Excel Diagnostics and Nuclear Oncology Center
Jules Bordet Institute
4SC AG
Stanford University
MultiVir, Inc.
National Institutes of Health Clinical Center (CC)
Philogen S.p.A.
University Hospital, Grenoble
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)